Holger Rabenau
Overview
Explore the profile of Holger Rabenau including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
16
Citations
3920
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Grikscheit K, Berger A, Rabenau H, Kohmer N, Appel K, Scherer M, et al.
Emerg Microbes Infect
. 2025 Jan;
14(1):2459137.
PMID: 39868965
Viremia defined as detectable SARS-CoV-2 RNA in the blood is a potential marker of disease severity and prognosis in COVID-19 patients. Here, we determined the frequency of viremia in serum...
2.
Hoehl S, Kreutzer E, Schenk B, Westhaus S, Foppa I, Herrmann E, et al.
Clin Infect Dis
. 2021 Jan;
73(9):e3036-e3041.
PMID: 33388748
Background: With the pandemic of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) ongoing in Europe in June 2020, day care centers were reopened in the state of Hesse, Germany, after...
3.
Muenchhoff M, Mairhofer H, Nitschko H, Grzimek-Koschewa N, Hoffmann D, Berger A, et al.
Euro Surveill
. 2020 Jun;
25(24).
PMID: 32583765
Containment strategies and clinical management of coronavirus disease (COVID-19) patients during the current pandemic depend on reliable diagnostic PCR assays for the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Here,...
4.
Hoehl S, Rabenau H, Berger A, Kortenbusch M, Cinatl J, Bojkova D, et al.
N Engl J Med
. 2020 Feb;
382(13):1278-1280.
PMID: 32069388
No abstract available.
5.
Vogel J, Schmidt S, Schmidt D, Rothweiler F, Koch B, Baer P, et al.
Cells
. 2019 Dec;
9(1).
PMID: 31861948
The thrombopoietin receptor agonist eltrombopag was successfully used against human cytomegalovirus (HCMV)-associated thrombocytopenia refractory to immunomodulatory and antiviral drugs. These effects were ascribed to the effects of eltrombopag on megakaryocytes....
6.
Raabe V, Kann G, Ribner B, Morales A, Varkey J, Mehta A, et al.
Clin Infect Dis
. 2017 Oct;
65(5):855-859.
PMID: 29017278
Two patients with Lassa fever are described who are the first human cases treated with a combination of ribavirin and favipiravir. Both patients survived but developed transaminitis and had prolonged...
7.
Berger A, Rabenau H, Allwinn R, Doerr H
J Clin Virol
. 2008 Jul;
43(2):158-61.
PMID: 18635393
Background: An improved test version of the Abbott ARCHITECT anti-hepatitis C virus (HCV) test became available at the end of 2005. Study Design: We compared the new test version with...
8.
Kampf G, Steinmann J, Rabenau H
BMC Infect Dis
. 2007 Feb;
7:5.
PMID: 17291338
Background: A procedure for including activity against enveloped viruses in the post-contamination treatment of hands has been recommended, but so far no European standard is available to implement it. In...
9.
Giroglou T, Cinatl Jr J, Rabenau H, Drosten C, Schwalbe H, Doerr H, et al.
J Virol
. 2004 Aug;
78(17):9007-15.
PMID: 15308697
The worldwide outbreak of severe acute respiratory syndrome (SARS) was shown to be associated with a novel coronavirus (CoV) now called SARS CoV. We report here the generation of SARS...
10.
Yamamoto N, Yang R, Yoshinaka Y, Amari S, Nakano T, Cinatl J, et al.
Biochem Biophys Res Commun
. 2004 May;
318(3):719-25.
PMID: 15144898
A novel coronavirus has been identified as an etiological agent of severe acute respiratory syndrome (SARS). To rapidly identify anti-SARS drugs available for clinical use, we screened a set of...